Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Buy at StockNews.com

StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a research note published on Tuesday morning.

A number of other brokerages have also issued reports on REGN. Royal Bank of Canada reiterated an outperform rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Barclays upped their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. Truist Financial restated a buy rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a report on Wednesday, March 13th. Finally, Cantor Fitzgerald restated a neutral rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $977.77.

Regeneron Pharmaceuticals Trading Up 2.1 %

Shares of REGN stock opened at $957.00 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33. The stock has a fifty day moving average of $944.24 and a two-hundred day moving average of $895.54. The firm has a market capitalization of $105.04 billion, a PE ratio of 27.54, a price-to-earnings-growth ratio of 2.59 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the firm posted $10.96 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals will post 38.86 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 10,095 shares of company stock worth $9,664,476 in the last quarter. 8.83% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Accurate Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $229,000. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 135.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 10,126 shares of the biopharmaceutical company’s stock valued at $8,333,000 after purchasing an additional 5,832 shares in the last quarter. Kingswood Wealth Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 122.0% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 846 shares of the biopharmaceutical company’s stock valued at $696,000 after purchasing an additional 465 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the 3rd quarter. Maryland State Retirement & Pension System now owns 7,980 shares of the biopharmaceutical company’s stock valued at $6,567,000 after purchasing an additional 65 shares in the last quarter. Finally, Tectonic Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the 3rd quarter. Tectonic Advisors LLC now owns 769 shares of the biopharmaceutical company’s stock valued at $633,000 after purchasing an additional 35 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.